Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Start of Photofrin trial delayed

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Apr 05, 2021 5:34pm

178 Views

Post# 32938946

RE:RE:RE:Start of Photofrin trial delayed

Eoganacht wrote: I don't think there's any chance this trial could change it's pdc to TLD1433. I think that would make it so substantially different that it would require a new application to the FDA. However, Roswell Park is going to conduct a second, similar phase 1 trial and they are not being very forthcoming with the details. Maybe they are considering the use of TLD1433 in this one. A while back I wrote Lumeda and asked them if they were considering TLD1433 for the second trial and they responded that the choice of PS is up to Roswell Park, not them. Here is the little information Lumeda has posted about it.

"...the study plan will include assessment of the effect of PDT on the immune contexture of NSCLC patients, as well as establishing safety of PDT (Phase I study) when used in Combination PDT + Immunotherapy.

Phase I Combination PDT-Immunotherapy

Design

Approval

Q1-21

Study Start

Q2-21

Primary Completion

Q2-22

Initial Results

Q1-22

Phase I Combination PDT-Immunotherapy (Information to be published once listed on the NIH clinical studies registry)

Title: TBD

ClinicalTrials.gov Identifier: TBD

Sponsor: Roswell Park Comprehensive Cancer Center

Summary: TBD

Primary Objective: TBD

Secondary Objectives: TBD

patience69 wrote: Just sort of curious. Does anyone here still feel that there is a chance that this trial could change to include 1433? Or does our new relationship at St Mikes mean we will likely be doing our own thing?